Abstract OBJECTIVE: This study examined the effects of curcumin on intestinal histopathological changes, cyclooxygenase-2 (COX-2) expression, and tumor necrosis factor-α (TNF-α) and interleukin-10 (IL-10) concentrations in neonatal rats with necrotizing enterocolitis (NEC) , in order to investigate the effects of curcumin against NEC. METHODS: Forty neonatal rats were randomly divided into four groups (n=10 each): normal control, solvent control, NEC model, and curcumin intervention. The general situations of rats were observed for 3 consecutive days, and the rats were then sacrificed on the 4th day. Intestinal tissues were obtained for examining the histopathological changes, COX-2 expression, and TNF-α and IL-10 concentrations. RESULTS: Curcumin treatment ameliorated the general situations and histopathological signs in rats with NEC. TNF-α and IL-10 concentrations in the NEC model and the curcumin intervention groups increased significantly compared with those in the normal and solvent control groups (P<0.05). The concentration of TNF-α decreased (P<0.05), while the concentration of IL-10 increased significantly in the curcumin intervention group in comparison with the NEC model group (P<0.05). Immunohistochemistry results indicated that the positive expression of COX-2 in the curcumin intervention group was significantly lower than that in the NEC model group. CONCLUSIONS: Curcumin has protective effects against NEC in neonatal rats, possibly through inhibiting COX-2 expression, reducing TNF-α content, and increasing IL-10 content.［Chin J Contemp Pediatr, 2010, 12 (2):132-136］
JIA Sheng-Hua,WEI Hong,YU Jia-Lin et al. Protective effects of curcumin on neonatal rats with necrotizing enterocolitis[J]. 中国当代儿科杂志, 2010, 12(2): 132-136.
JIA Sheng-Hua,WEI Hong,YU Jia-Lin et al. Protective effects of curcumin on neonatal rats with necrotizing enterocolitis[J]. CJCP, 2010, 12(2): 132-136.
［4］Auestad N, Korsak RA, Bergstrom JD, Edmond J. Milk-substitutes comparable to rat′s milk; their preparation, composition and impact on development and metabolism in the artificially reared rat［J］. Br J Nutr, 1989, 61(3):495-518.
［5］Nadler EP, Dickinson E, Knisely A, Zhang XR, Boyle P, Beer-Stolz D, et al. Expression of inducible nitric oxide synthase and interleukin-12 in experimental necrotizing enterocolitis［J］. J Surg Res, 2000, 92(1):71-77.
［6］Hsuch W, Caplan MS, Qu XW, Tan XD, De Plan IG, Gonzalez-Crussi F. Neonatal necrotizing enterocolitis: clinical considerations and pathogenetic concepts［J］. Pediatr Dev Pathol, 2003, 6(1):6-23.
［7］Edelson MB, Bagwell CE, Rozycki HJ. Circulating pro-and counterinflammatory cytokine levels and severity in necrotizing enterocolitis［J］. Pediatrics, 1999, 103(4):766-771.
［8］Zhang M, Deng CS, Zheng JJ, Xia J. Curcumin regulated shift from Th1 to Th2 in trinitrobenzene sulphonic acid-induced chronic colitis［J］. Acta Pharmacol Sin, 2006, 27(8):1071-1077.
［9］Siddiqui AM, Cui X, Wu R, Dong W, Zhou M, Hu M, et al. The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma［J］. Crit Care Med, 2006, 34(7):1874-1882.
［11］Ramsay RG, Ciznadija D, Vanevski M, Mantamadiotis T. Transcriptional regulation of cyclo-oxygenase expression: three pillars of control［J］. Int J Immunopathol Pharmacol, 2003, 16(2 Suppl):59-67.
［12］D′Halluin PN, Turlin B, Polard E, Dinasquet M, Pagenault M, Rioux N, et al. Selective COX-2 inhibitor-associated colitis: two case reports［J］. Gastroenterol Clin Biol, 2003, 27(10):932-935.
［13］Chung DH, Ethridge RT, Kim S, Owens-Stovall S, Hernandez A, Kelly DR, et al. Molecular mechanisms contributing to necrotizing enterocolitis［J］.Ann Surg, 2001, 233(6):835-842.
［14］Guthrie SO, Gordon PV, Thomas V, Thorp JA, Peabody J, Clark RH. Necrotizing enterocolitis among neonates in the United States［J］. J Perinatol, 2003, 23(4):278-285.
［15］Jobin C, Bradham CA, Russo MP, Jurna B, Narula AS, Brenner DA, et al. Curcumin blocks cytokine-mediated NFkappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity［J］. J Immunol, 1999, 163(6):3474-3483.
